Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 10/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297611 | 0.94 | SRC (0.52) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL8960 | 0.94 | SRC (0.52) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL3231833 | 0.92 | SLC2A1 (0.47) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL4018984 | 0.91 | SLC2A1 (0.46) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL3725738 | 0.91 | SLC2A1 (0.46) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL27576840 | 0.90 | SLC2A1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL13090425 | 0.90 | SLC2A1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL4230774 | 0.86 | SLC2A1 (0.42) | SLC2A1PARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL4226040 | 0.85 | IP6K1 (0.57) | SLC2A1PARP1IP6K1ALOX15SMN1; SMN2 | |
| SCHEMBL5500065 | 0.85 | SLC2A1 (0.46) | SLC2A1PARP1CHEK1PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3015460-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | CERBIOS-PHARMA S A (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-9452220-B2 | Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9428468-B2 | Process for the preparation of erlotinib | CERBIOS-PHARMA SA (CH) | 2016-08-30 | — | — | US | disclosed |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-23 | — | — | US | disclosed |
| EP-3015460-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | Cerbios-Pharma S.A. (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-20160115137-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | CERBIOS-PHARMA SA (CH) | 2016-04-28 | — | — | US | disclosed |
| EP-2162444-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LTD (IN) | 2014-06-04 | — | — | EP | disclosed |
| US-8389531-B2 | Process for erlotinib hydrochloride | HETERO DRUGS LIMITED (IN) | 2013-03-05 | — | — | US | disclosed |
| US-8343950-B2 | Cell surface tyrosine receptor kinase inhibitors; pyrogen-free; lung cancer; benign prostatic hyperplasia | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343950-B2 | Cell surface tyrosine receptor kinase inhibitors; pyrogen-free; lung cancer; benign prostatic hyperplasia | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009121042-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009007984-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007060691-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | SLC2A1 3778/4885PARP1 1318/4885CHEK1 323/4885 |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | EGFR, CHUK, ERBB2 | SLC2A1 3052/4885PARP1 3733/4885CHEK1 3185/4885 |
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | SLC2A1 2511/4885PARP1 2042/4885CHEK1 354/4885 |
| US-20160115137-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | EGFR, KRAS, MET | SLC2A1 2124/4885PARP1 2825/4885CHEK1 252/4885 |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | SLC2A1 2511/4885PARP1 2042/4885CHEK1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.